{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:34Z","timestamp":1786986874876,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clineuro.2024.108409","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T19:20:47Z","timestamp":1719602447000},"page":"108409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Predicting response to chemotherapy in brain tumor patients based on MRI features"],"prefix":"10.1016","volume":"244","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4281-7436","authenticated-orcid":false,"given":"Rabeet","family":"Tariq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clineuro.2024.108409_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40336-022-00489-6","article-title":"Epidemiology, risk factors, and prognostic factors of gliomas","volume":"10","author":"Pellerino","year":"2022","journal-title":"Clin. Transl. Imaging"},{"issue":"8","key":"10.1016\/j.clineuro.2024.108409_bib2","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncol."},{"issue":"8","key":"10.1016\/j.clineuro.2024.108409_bib3","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/annonc\/mdx230","article-title":"Surgical resection versus watchful waiting in low-grade gliomas","volume":"28","author":"Jakola","year":"2017","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"issue":"14","key":"10.1016\/j.clineuro.2024.108409_bib4","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"29","key":"10.1016\/j.clineuro.2024.108409_bib5","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1200\/JCO.2016.68.1585","article-title":"Phase II weekly vinblastine for chemotherapy-na\u00efve children with progressive low-grade glioma: a Canadian pediatric brain tumor consortium study","volume":"34","author":"Lassaletta","year":"2016","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"25","key":"10.1016\/j.clineuro.2024.108409_bib6","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1200\/JCO.2011.35.8598","article-title":"Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802","volume":"30","author":"Shaw","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108409_bib7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3747\/co.25.3680","article-title":"Procarbazine, lomustine and vincristine toxicity in low-grade gliomas","volume":"25","author":"Jutras","year":"2018","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108409_bib8","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.clineuro.2024.108409_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clineuro.2024.108409_bib10","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/j.wneu.2021.07.002","article-title":"Upfront therapy of aggressive\/high-risk low-grade glioma: single-institution outcome analysis of temozolomide-based radio-chemotherapy and adjuvant chemotherapy","volume":"154","author":"Anand","year":"2021","journal-title":"World Neurosurg."},{"issue":"20","key":"10.1016\/j.clineuro.2024.108409_bib11","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.clineuro.2024.108409_bib12","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/CCO.0b013e3282f075f3","article-title":"Molecular genetic markers as predictors of response to chemotherapy in gliomas","volume":"19","author":"Idbaih","year":"2007","journal-title":"Curr. Opin. Oncol."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108409_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11060-014-1443-0","article-title":"IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy","volume":"118","author":"Minniti","year":"2014","journal-title":"J. Neurooncol."},{"issue":"10","key":"10.1016\/j.clineuro.2024.108409_bib14","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clineuro.2024.108409_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107922","article-title":"Genotoxic therapy and resistance mechanism in gliomas","volume":"228","author":"Lang","year":"2021","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.clineuro.2024.108409_bib16","first-page":"noac188","article-title":"EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors","author":"Rud\u00e0","year":"2022","journal-title":"Neuro-Oncol."},{"issue":"3","key":"10.1016\/j.clineuro.2024.108409_bib17","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2019-0012","article-title":"The role of chemotherapy in the treatment of central neurocytoma","volume":"8","author":"Johnson","year":"2019","journal-title":"CNS Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108409_bib18","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2020-0027","article-title":"Adult pilocytic astrocytoma in the molecular era: a comprehensive review","volume":"10","author":"Gregory","year":"2021","journal-title":"CNS Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108409_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial","volume":"23","author":"Wen","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.clineuro.2024.108409_bib20","doi-asserted-by":"crossref","DOI":"10.2217\/fnl-2020-0003","article-title":"Glioneuronal tumors: clinicopathological findings and treatment options","author":"Gatto","year":"2020","journal-title":"Future Neurol."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108409_bib21","first-page":"750","article-title":"Pediatric low-grade gliomas: implications of the biologic era","volume":"19","author":"Packer","year":"2017","journal-title":"Neuro-Oncol."},{"issue":"7","key":"10.1016\/j.clineuro.2024.108409_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2024.108409_bib23","article-title":"Comparison of epidemiology, treatments, and outcomes in pediatric versus adult ependymoma","volume":"2","author":"Elsamadicy","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"issue":"5","key":"10.1016\/j.clineuro.2024.108409_bib24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across All CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.clineuro.2024.108409_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2011.07.007","article-title":"Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma","volume":"20","author":"Witt","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.clineuro.2024.108409_bib26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3171\/jns.1998.88.4.0695","article-title":"Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children\u2019s Cancer Group","volume":"88","author":"Robertson","year":"1998","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108409_bib27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11060-013-1111-9","article-title":"Outcome of infants and young children with newly diagnosed ependymoma treated on the \u201cHead Start\u201d III prospective clinical trial","volume":"113","author":"Venkatramani","year":"2013","journal-title":"J. Neurooncol."},{"issue":"8","key":"10.1016\/j.clineuro.2024.108409_bib28","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1470-2045(07)70208-5","article-title":"Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG\/SIOP prospective study","volume":"8","author":"Grundy","year":"2007","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.clineuro.2024.108409_bib29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11060-007-9428-x","article-title":"Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors","volume":"85","author":"Wrede","year":"2007","journal-title":"J. Neurooncol."},{"issue":"4","key":"10.1016\/j.clineuro.2024.108409_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000120900","article-title":"Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group","volume":"22","author":"Duffner","year":"1995","journal-title":"Pediatr. Neurosurg."},{"issue":"3","key":"10.1016\/j.clineuro.2024.108409_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11060-021-03942-0","article-title":"Final results of the Choroid Plexus Tumor study CPT-SIOP-2000","volume":"156","author":"Wolff","year":"2022","journal-title":"J. Neurooncol"},{"issue":"12","key":"10.1016\/j.clineuro.2024.108409_bib32","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1177\/0883073815600866","article-title":"Medulloblastoma","volume":"31","author":"Millard","year":"2016","journal-title":"J. Child Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2024.108409_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00401-012-0958-8","article-title":"Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas","volume":"123","author":"Kool","year":"2012","journal-title":"Acta Neuropathol. (Berl.)"},{"issue":"10","key":"10.1016\/j.clineuro.2024.108409_bib34","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(06)70867-1","article-title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial","volume":"7","author":"Gajjar","year":"2006","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.clineuro.2024.108409_bib35","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2006.06.4980","article-title":"Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"24","author":"Packer","year":"2006","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.clineuro.2024.108409_bib36","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa042176","article-title":"Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone","volume":"352","author":"Rutkowski","year":"2005","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.clineuro.2024.108409_bib37","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.wneu.2022.04.004","article-title":"The role of chemotherapy in the treatment of adult medulloblastoma","volume":"163","author":"Chen","year":"2022","journal-title":"World Neurosurg."},{"issue":"30","key":"10.1016\/j.clineuro.2024.108409_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029372","article-title":"Meta of classical chemotherapy compared with high-dose chemotherapy and autologous stem cell rescue in newly diagnosed medulloblastoma after radiotherapy","volume":"101","author":"Zhang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clineuro.2024.108409_bib39","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.canlet.2021.07.020","article-title":"Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation","volume":"520","author":"Song","year":"2021","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.clineuro.2024.108409_bib40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/1097-0142(20000901)89:5<1102::AID-CNCR20>3.0.CO;2-L","article-title":"Recurrence of meningiomas","volume":"89","author":"Yamasaki","year":"2000","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clineuro.2024.108409_bib41","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1634\/theoncologist.2011-0193","article-title":"Update on meningiomas","volume":"16","author":"Saraf","year":"2011","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.clineuro.2024.108409_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.6004\/jnccn.2011.0036","article-title":"Central nervous system cancers","volume":"9","author":"Brem","year":"2011","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"8","key":"10.1016\/j.clineuro.2024.108409_bib43","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-\u03b1 for recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clineuro.2024.108409_bib44","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clineuro.2024.108409_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J. Neurooncol"},{"issue":"11","key":"10.1016\/j.clineuro.2024.108409_bib46","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.6004\/jnccn.2020.0052","article-title":"Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Nabors","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"issue":"0","key":"10.1016\/j.clineuro.2024.108409_bib47","first-page":"1","article-title":"How useful is chemotherapy for atypical and anaplastic meningiomas?","volume":"0","author":"Drappatz","year":"2022","journal-title":"Expert Opin. Pharm."},{"issue":"4","key":"10.1016\/j.clineuro.2024.108409_bib48","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00330-020-07581-3","article-title":"An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas","volume":"31","author":"Wang","year":"2021","journal-title":"Eur. Radiol."},{"issue":"8","key":"10.1016\/j.clineuro.2024.108409_bib49","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3390\/cancers12082284","article-title":"Multi-parametric deep learning model for prediction of overall survival after postoperative concurrent chemoradiotherapy in glioblastoma patients","volume":"12","author":"Yoon","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clineuro.2024.108409_bib50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6605712","article-title":"Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide","volume":"103","author":"van Nifterik","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clineuro.2024.108409_bib51","first-page":"1","article-title":"Advances in the management of glioblastoma: the role of temozolomide and MGMT testing","volume":"5","author":"Thomas","year":"2012","journal-title":"Clin. Pharm. Adv. Appl."},{"issue":"5","key":"10.1016\/j.clineuro.2024.108409_bib52","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3174\/ajnr.A7029","article-title":"MRI-based deep-learning method for determining glioma MGMT promoter methylation status","volume":"42","author":"Yogananda","year":"2021","journal-title":"Am. J. Neuroradiol."},{"issue":"2","key":"10.1016\/j.clineuro.2024.108409_bib53","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00330-018-5575-z","article-title":"A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication","volume":"29","author":"Wei","year":"2019","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.clineuro.2024.108409_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2019.108714","article-title":"Fusion radiomics features from conventional MRI predict MGMT promoter methylation status in lower grade gliomas","volume":"121","author":"Jiang","year":"2019","journal-title":"Eur. J. Radio."},{"issue":"9","key":"10.1016\/j.clineuro.2024.108409_bib55","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1007\/s00330-017-5302-1","article-title":"Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: a multicentre study","volume":"28","author":"Li","year":"2018","journal-title":"Eur. Radiol."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108409_bib56","doi-asserted-by":"crossref","first-page":"660","DOI":"10.18632\/oncotarget.26578","article-title":"Preoperative MRI-radiomics features improve prediction of survival in glioblastoma patients over MGMT methylation status alone","volume":"10","author":"Tixier","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.clineuro.2024.108409_bib57","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.mri.2020.09.017","article-title":"Machine learning-based radiomic, clinical and semantic feature analysis for predicting overall survival and MGMT promoter methylation status in patients with glioblastoma","volume":"74","author":"Lu","year":"2020","journal-title":"Magn. Reson. Imaging"},{"issue":"12","key":"10.1016\/j.clineuro.2024.108409_bib58","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/neuonc\/nox092","article-title":"Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab","volume":"19","author":"Grossmann","year":"2017","journal-title":"Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108409_bib59","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3174\/ajnr.A5620","article-title":"Edge contrast of the FLAIR hyperintense region predicts survival in patients with high-grade gliomas following treatment with bevacizumab","volume":"39","author":"Bahrami","year":"2018","journal-title":"AJNR Am. J. Neuroradiol."},{"issue":"23","key":"10.1016\/j.clineuro.2024.108409_bib60","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1158\/1078-0432.CCR-16-0702","article-title":"Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response","volume":"22","author":"Kickingereder","year":"2016","journal-title":"Clin. Cancer Res. J. Am. Assoc. Cancer Res."},{"issue":"20","key":"10.1016\/j.clineuro.2024.108409_bib61","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/1078-0432.CCR-20-1264","article-title":"A radiomics model for predicting the response to bevacizumab in brain necrosis after radiotherapy","volume":"26","author":"Cai","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.clineuro.2024.108409_bib62","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3390\/diagnostics11071263","article-title":"Machine-learning-based radiomics MRI model for survival prediction of recurrent glioblastomas treated with bevacizumab","volume":"11","author":"Ammari","year":"2021","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.clineuro.2024.108409_bib63","first-page":"171","article-title":"Assessment of concurrent stereotactic radiosurgery and bevacizumab treatment of recurrent malignant gliomas using multi-modality MRI imaging and radiomics analysis","volume":"5","author":"Wang","year":"2018","journal-title":"J. Radio. SBRT"},{"key":"10.1016\/j.clineuro.2024.108409_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116433","article-title":"Cerebral blood volume and apparent diffusion coefficient \u2013 Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma","volume":"405","author":"Petrova","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.clineuro.2024.108409_bib65","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/jon.12903","article-title":"Glioblastoma radiomics to predict survival: diffusion characteristics of surrounding nonenhancing tissue to select patients for extensive resection","volume":"31","author":"Pasquini","year":"2021","journal-title":"J. Neuroimaging"},{"issue":"1","key":"10.1016\/j.clineuro.2024.108409_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12880-020-00545-5","article-title":"Differentiation of pseudoprogression from true progressionin glioblastoma patients after standard treatment: a machine learning strategy combinedwith radiomics features from T1-weighted contrast-enhanced imaging","volume":"21","author":"Sun","year":"2021","journal-title":"BMC Med. Imaging"},{"issue":"9","key":"10.1016\/j.clineuro.2024.108409_bib67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neurol.2019.01.400","article-title":"Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients","volume":"175","author":"Bani-Sadr","year":"2019","journal-title":"Rev. Neurol. (Paris)"},{"issue":"3","key":"10.1016\/j.clineuro.2024.108409_bib68","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/neuonc\/noy133","article-title":"Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients","volume":"21","author":"Kim","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.clineuro.2024.108409_bib69","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.3390\/cancers12123835","article-title":"FET PET radiomics for differentiating pseudoprogression from early tumor progression in glioma patients post-chemoradiation","volume":"12","author":"Lohmann","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.clineuro.2024.108409_bib70","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.3390\/cancers12113080","article-title":"A preliminary study on machine learning-based evaluation of static and dynamic FET-PET for the detection of pseudoprogression in patients with IDH-wildtype glioblastoma","volume":"12","author":"Kebir","year":"2020","journal-title":"Cancers"},{"issue":"supplement 1","key":"10.1016\/j.clineuro.2024.108409_bib71","article-title":"Identification of a radiomic signature to distinguish recurrence from radiation-induced necrosis in treated glioblastomas using machine learning methods on dual-point 18F-FDOPA PET images","volume":"60","author":"Orlhac","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"13","key":"10.1016\/j.clineuro.2024.108409_bib72","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1158\/1078-0432.CCR-21-0471","article-title":"Diagnosis of pseudoprogression following lomustine\u2013temozolomide chemoradiation in newly diagnosed glioblastoma patients using FET-PET","volume":"27","author":"Werner","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724002968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846724002968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:04:19Z","timestamp":1749895459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846724002968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":72,"alternative-id":["S0303846724002968"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108409","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting response to chemotherapy in brain tumor patients based on MRI features","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2024.108409","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108409"}}